AZD8529 Multiple Ascending Dose Study in Healthy Subjects

Study identifier:D1960C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8529 When Given as Single and Multiple Ascending Oral Doses in Healthy Subjects

Medical condition

Healthy Volunteer

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD8529, Placebo

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Oct 2008

Primary Completion Date: -

Study Completion Date: 01 Mar 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Other

Verification:

Verified 01 Jun 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1	Drug: AZD8529 oral
Placebo Comparator: 2	Drug: Placebo oral

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Mark Smith

AstraZeneca